LeMaitre Vascular Inc (LMAT)

Currency in USD
86.54
+2.17(+2.58%)
Real-time Data·
LMAT Scorecard
Full Analysis
Has raised its dividend for 14 consecutive years
LMAT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
83.6286.54
52 wk Range
71.42109.58
Key Statistics
Prev. Close
84.36
Open
84.22
Day's Range
83.62-86.54
52 wk Range
71.42-109.58
Volume
115.44K
Average Volume (3m)
154.76K
1-Year Change
-0.76%
Book Value / Share
15.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LMAT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
104.50
Upside
+20.75%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

LeMaitre Vascular Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

LeMaitre Vascular Inc Company Profile

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LeMaitre Vascular Inc SWOT Analysis


Niche Market Dominance
LeMaitre Vascular's strategic focus on underserved vascular device markets under $200 million has solidified its leadership position and pricing powe
Financial Resilience
Explore LMAT's robust 13.19% revenue growth and consistent dividend increases, showcasing its financial strength despite margin pressures
Global Expansion Plans
Delve into LeMaitre's ambitious international growth strategy, particularly in Europe, and its potential impact on future revenue streams
Analyst Perspectives
With price targets ranging from $92 to $113, analysts weigh LMAT's growth potential against valuation concerns in a competitive landscape
Read full SWOT analysis

LeMaitre Vascular Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue reached $58.8M (13% organic growth), surpassing forecasts, but EPS of $0.48 missed expectations
  • Stock declined 3.88% after-hours despite strong revenue, reflecting concerns over EPS miss and future earnings pressures
  • 2025 sales guidance raised to $245M from $239M, with organic growth forecast increased to 13% from 10%
  • Significant growth in EMEA and Americas regions; expansion of sales force and new product launches planned
  • Management confident in positioning against tariffs; exploring M&A opportunities in $15M-$150M revenue range
Last Updated: 01/05/2025, 23:06
Read Full Transcript

Compare LMAT to Peers and Sector

Metrics to compare
LMAT
Peers
Sector
Relationship
P/E Ratio
43.1x32.1x−0.5x
PEG Ratio
1.390.540.00
Price/Book
5.6x2.7x2.6x
Price / LTM Sales
8.6x3.6x3.3x
Upside (Analyst Target)
28.0%0.5%43.5%
Fair Value Upside
Unlock1.4%6.3%Unlock

Analyst Ratings

5 Buy
6 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 104.50
(+20.75% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.01%
Dividend Yield
0.95%
Industry Median 1.32%
Annualised payout
0.80
Paid quarterly
5-Years Growth
+14.21%
Growth Streak

Earnings

Latest Release
May 08, 2025
EPS / Forecast
0.48 / 0.51
Revenue / Forecast
59.87M / 58.13M
EPS Revisions
Last 90 days

LMAT Income Statement

People Also Watch

284.52
RMD
-2.37%
106.19
DECK
+1.01%
184.53
BMI
-0.72%
256.68
CRS
+1.45%
124.62
FSS
+0.01%

FAQ

What Stock Exchange Does LeMaitre Vascular Trade On?

LeMaitre Vascular is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for LeMaitre Vascular?

The stock symbol for LeMaitre Vascular is "LMAT."

What Is the LeMaitre Vascular Market Cap?

As of today, LeMaitre Vascular market cap is 1.96B.

What Is LeMaitre Vascular's Earnings Per Share (TTM)?

The LeMaitre Vascular EPS (TTM) is 2.01.

When Is the Next LeMaitre Vascular Earnings Date?

LeMaitre Vascular will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is LMAT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has LeMaitre Vascular Stock Split?

LeMaitre Vascular has split 0 times.

How Many Employees Does LeMaitre Vascular Have?

LeMaitre Vascular has 658 employees.

What is the current trading status of LeMaitre Vascular (LMAT)?

As of 05 Aug 2025, LeMaitre Vascular (LMAT) is trading at a price of 86.54, with a previous close of 84.36. The stock has fluctuated within a day range of 83.62 to 86.54, while its 52-week range spans from 71.42 to 109.58.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.